{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:21:38Z","timestamp":1789507298984,"version":"build-2803163510"},"reference-count":24,"publisher":"Rockefeller University Press","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,5]]},"abstract":"<jats:p>Primary hemophagocytic lymphohistiocytosis (pHLH) is a group of genetically determined disorders characterized by severe and fulminant systemic inflammation, cytopenia, and multiple organ involvement. A dexamethasone-and-etoposide\u2013based HLH-2004 protocol is widely used to treat pHLH, yet often fails to produce the disease control required for the next treatment step: hematopoietic stem cell transplantation (HSCT). We report on the use of the interferon gamma inhibitor emapalumab in seven children aged 6\u201339 months with pHLH. Three patients received emapalumab at an average starting dose of 1.7 mg\/kg and had no active HLH by median day 28. Four patients received emapalumab at an average starting dose of 7.2 mg\/kg and had no active HLH by median day 14 (P = 0,0015). We suggest that the higher starting dose of emapalumab, as well as its combination with Janus kinase inhibitors, might increase the remission rate in pHLH and the success of subsequent HSCT.<\/jats:p>","DOI":"10.70962\/jhi.20250122","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:21:41Z","timestamp":1761805301000},"update-policy":"https:\/\/doi.org\/10.70962\/jhi.crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical experience with emapalumab treatment in a group of children with primary hemophagocytic lymphohistiocytosis"],"prefix":"10.70962","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9857-4456","authenticated-orcid":true,"given":"Yulia","family":"Rodina","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02h8dsx08","id-type":"ROR","asserted-by":"publisher"}],"name":"Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology 1 , Department of Immunology, Moscow,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-9957","authenticated-orcid":true,"given":"Vasiliy","family":"Burlakov","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02h8dsx08","id-type":"ROR","asserted-by":"publisher"}],"name":"Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology 1 , Department of Immunology, Moscow,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varvara","family":"Brilliantova","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02h8dsx08","id-type":"ROR","asserted-by":"publisher"}],"name":"Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology 1 , Department of Immunology, Moscow,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5132-1267","authenticated-orcid":true,"given":"Anna","family":"Roppelt","sequence":"additional","affiliation":[{"name":"Moscow City Hospital 52 2 , Moscow,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3564-6496","authenticated-orcid":true,"given":"Nelli","family":"Kan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02h8dsx08","id-type":"ROR","asserted-by":"publisher"}],"name":"Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology 1 , Department of Immunology, Moscow,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1258-8281","authenticated-orcid":true,"given":"Ulijna","family":"Petrova","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02h8dsx08","id-type":"ROR","asserted-by":"publisher"}],"name":"Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology 1 , Department of Immunology, Moscow,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7634-2053","authenticated-orcid":true,"given":"Elena","family":"Raykina","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02h8dsx08","id-type":"ROR","asserted-by":"publisher"}],"name":"Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology 1 , Department of Immunology, Moscow,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6148-7209","authenticated-orcid":true,"given":"Dmitry","family":"Pershin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02h8dsx08","id-type":"ROR","asserted-by":"publisher"}],"name":"Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology 1 , Department of Immunology, Moscow,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Balashov","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02h8dsx08","id-type":"ROR","asserted-by":"publisher"}],"name":"Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology 1 , Department of Immunology, Moscow,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-6698","authenticated-orcid":true,"given":"Alexey","family":"Maschan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02h8dsx08","id-type":"ROR","asserted-by":"publisher"}],"name":"Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology 1 , Department of Immunology, Moscow,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2322-5734","authenticated-orcid":true,"given":"Galina","family":"Novichkova","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02h8dsx08","id-type":"ROR","asserted-by":"publisher"}],"name":"Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology 1 , Department of Immunology, Moscow,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3113-4939","authenticated-orcid":true,"given":"Anna","family":"Shcherbina","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02h8dsx08","id-type":"ROR","asserted-by":"publisher"}],"name":"Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology 1 , Department of Immunology, Moscow,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"2025121109255788400_bib1","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1182\/blood.2019000936","article-title":"Pediatric hemophagocytic lymphohistiocytosis","volume":"135","author":"Canna","year":"2020","journal-title":"Blood"},{"key":"2025121109255788400_bib2","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.jaip.2018.05.031","article-title":"Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: Consensus statements by the HLH steering committee of the histiocyte society","volume":"6","author":"Ehl","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2025121109255788400_bib3","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1182\/blood-2018-01-828277","article-title":"Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies","volume":"132","author":"Allen","year":"2018","journal-title":"Blood"},{"key":"2025121109255788400_bib4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr. Blood Cancer"},{"key":"2025121109255788400_bib5","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: Long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood"},{"key":"2025121109255788400_bib6","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1542\/peds.2006-3164","article-title":"Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: A single-center retrospective report of 38 patients","volume":"120","author":"Mahlaoui","year":"2007","journal-title":"Pediatrics"},{"key":"2025121109255788400_bib7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13054-020-02878-7","article-title":"IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome","volume":"24","author":"Dufranc","year":"2020","journal-title":"Crit. Care"},{"key":"2025121109255788400_bib8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/ejh.14029","article-title":"Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis\/macrophage activation syndrome: A systematic review","volume":"111","author":"Charlesworth","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"2025121109255788400_bib9","doi-asserted-by":"publisher","first-page":"614704","DOI":"10.3389\/fimmu.2021.614704","article-title":"Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis","volume":"12","author":"Keenan","year":"2021","journal-title":"Front. Immunol."},{"key":"2025121109255788400_bib10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41584-021-00694-z","article-title":"Targeting interferon-\u03b3 in hyperinflammation: Opportunities and challenges","volume":"17","author":"De Benedetti","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"2025121109255788400_bib11","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025121109255788400_bib12","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","volume":"134","author":"Vallurupalli","year":"2019","journal-title":"Blood"},{"key":"2025121109255788400_bib13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13256-023-03808-1","article-title":"Successful use of emapalumab in refractory hemophagocytic lymphohistiocytosis in a child with Ch\u00e9diak-Higashi syndrome: A case report","volume":"17","author":"AlAhmari","year":"2023","journal-title":"J. Med. Case Rep."},{"key":"2025121109255788400_bib14","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1182\/bloodadvances.2023012217","article-title":"Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab","volume":"8","author":"Chandrakasan","year":"2024","journal-title":"Blood Adv."},{"key":"2025121109255788400_bib15","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1056\/NEJMc2020754","article-title":"Emapalumab in primary hemophagocytic lymphohistiocytosis","volume":"383","author":"Henter","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025121109255788400_bib16","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1182\/bloodadvances.2021004287","article-title":"IFN-\u03b3 signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS","volume":"5","author":"Lin","year":"2021","journal-title":"Blood Adv."},{"key":"2025121109255788400_bib17","doi-asserted-by":"crossref","DOI":"10.31525\/fda1-ucm626280.htm","article-title":"FDA approves emapalumab for hemophagocytic lymphohistiocytosis","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"2025121109255788400_bib18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29026","article-title":"Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective","volume":"68","author":"Triebwasser","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"2025121109255788400_bib19","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.3324\/haematol.2019.216101","article-title":"Role of interferon-\u03b3 in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"Merli","year":"2019","journal-title":"Haematologica"},{"key":"2025121109255788400_bib20","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood.2024025977","article-title":"Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism","volume":"144","author":"Verkamp","year":"2024","journal-title":"Blood"},{"key":"2025121109255788400_bib21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4331\/wjbc.v13.i4.72","article-title":"Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Rybicka-Ramos","year":"2022","journal-title":"World J. Biol. Chem."},{"key":"2025121109255788400_bib22","doi-asserted-by":"publisher","first-page":"1123104","DOI":"10.3389\/fped.2023.1123104","article-title":"Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome","volume":"11","author":"Chellapandian","year":"2023","journal-title":"Front. Pediatr."},{"key":"2025121109255788400_bib23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"De Benedetti","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"2025121109255788400_bib24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/ajcp\/aqw076","article-title":"Performances of the H-score for diagnosis of hemophagocytic lymphohistiocytosis in adult and pediatric patients","volume":"145","author":"Debaugnies","year":"2016","journal-title":"Am. J. Clin. Pathol."}],"container-title":["Journal of Human Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jhi\/article-pdf\/doi\/10.70962\/jhi.20250122\/1954793\/jhi_20250122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jhi\/article-pdf\/doi\/10.70962\/jhi.20250122\/1954793\/jhi_20250122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T14:26:03Z","timestamp":1765463163000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jhi\/article\/2\/1\/e20250122\/278565\/Clinical-experience-with-emapalumab-treatment-in-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,5]]}},"URL":"https:\/\/doi.org\/10.70962\/jhi.20250122","relation":{},"ISSN":["3065-8993"],"issn-type":[{"value":"3065-8993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"article-number":"e20250122"}}